Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia

Kris M. Mahadeo; Lucia Wolgast; Christine Mcmahon; Peter D. Cole

doi:10.1002/pbc.23026

Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia

Kris M. Mahadeo, Lucia Wolgast, Christine Mcmahon, Peter D. Cole

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Mastocytosis is primarily limited to the cutaneous variant in pediatric patients. Systemic mastocytosis (SM) has been associated with t(8;21) acute myeloid leukemia (AML) in adults. We provide the first report of a child with t(8;21) AML, diagnosed with asymptomatic SM following four cycles of chemotherapy. Unlike most adults with SM/AML, she was not found to have a c-KIT (D816V) mutation. SM persisted in the bone marrow after completion of chemotherapy, and her AML relapsed 9 months off-treatment. Although she achieved a second remission, mastocytosis persists in the marrow. Pediatric patients with t(8;21) AML/SM may represent a high-risk group despite favorable cytogenetics.

Original language	English (US)
Pages (from-to)	684-687
Number of pages	4
Journal	Pediatric Blood and Cancer
Volume	57
Issue number	4
DOIs	https://doi.org/10.1002/pbc.23026
State	Published - Oct 2011

Keywords

AML
Molecular diagnosis and therapy
Pediatric hematology/oncology
Systemic mastocytosis

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.23026

Cite this

@article{0b6d1bfb8e0d4e44a8a2fef99dc53203,

title = "Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia",

abstract = "Mastocytosis is primarily limited to the cutaneous variant in pediatric patients. Systemic mastocytosis (SM) has been associated with t(8;21) acute myeloid leukemia (AML) in adults. We provide the first report of a child with t(8;21) AML, diagnosed with asymptomatic SM following four cycles of chemotherapy. Unlike most adults with SM/AML, she was not found to have a c-KIT (D816V) mutation. SM persisted in the bone marrow after completion of chemotherapy, and her AML relapsed 9 months off-treatment. Although she achieved a second remission, mastocytosis persists in the marrow. Pediatric patients with t(8;21) AML/SM may represent a high-risk group despite favorable cytogenetics.",

keywords = "AML, Molecular diagnosis and therapy, Pediatric hematology/oncology, Systemic mastocytosis",

author = "Mahadeo, {Kris M.} and Lucia Wolgast and Christine Mcmahon and Cole, {Peter D.}",

year = "2011",

month = oct,

doi = "10.1002/pbc.23026",

language = "English (US)",

volume = "57",

pages = "684--687",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "4",

}

TY - JOUR

T1 - Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia

AU - Mahadeo, Kris M.

AU - Wolgast, Lucia

AU - Mcmahon, Christine

AU - Cole, Peter D.

PY - 2011/10

Y1 - 2011/10

N2 - Mastocytosis is primarily limited to the cutaneous variant in pediatric patients. Systemic mastocytosis (SM) has been associated with t(8;21) acute myeloid leukemia (AML) in adults. We provide the first report of a child with t(8;21) AML, diagnosed with asymptomatic SM following four cycles of chemotherapy. Unlike most adults with SM/AML, she was not found to have a c-KIT (D816V) mutation. SM persisted in the bone marrow after completion of chemotherapy, and her AML relapsed 9 months off-treatment. Although she achieved a second remission, mastocytosis persists in the marrow. Pediatric patients with t(8;21) AML/SM may represent a high-risk group despite favorable cytogenetics.

AB - Mastocytosis is primarily limited to the cutaneous variant in pediatric patients. Systemic mastocytosis (SM) has been associated with t(8;21) acute myeloid leukemia (AML) in adults. We provide the first report of a child with t(8;21) AML, diagnosed with asymptomatic SM following four cycles of chemotherapy. Unlike most adults with SM/AML, she was not found to have a c-KIT (D816V) mutation. SM persisted in the bone marrow after completion of chemotherapy, and her AML relapsed 9 months off-treatment. Although she achieved a second remission, mastocytosis persists in the marrow. Pediatric patients with t(8;21) AML/SM may represent a high-risk group despite favorable cytogenetics.

KW - AML

KW - Molecular diagnosis and therapy

KW - Pediatric hematology/oncology

KW - Systemic mastocytosis

UR - http://www.scopus.com/inward/record.url?scp=79961181551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961181551&partnerID=8YFLogxK

U2 - 10.1002/pbc.23026

DO - 10.1002/pbc.23026

M3 - Article

C2 - 21671435

AN - SCOPUS:79961181551

SN - 1545-5009

VL - 57

SP - 684

EP - 687

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 4

ER -

Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this